Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 8/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25814633 | 0.84 | CYP19A1 (0.36) | CYP19A1TRPV1NPC1RAB9AALDH1A1 | |
| SCHEMBL22134638 | 0.83 | ALDH1A1 (0.41) | CYP19A1TRPV1NPC1RAB9AALDH1A1 | |
| SCHEMBL25815359 | 0.81 | ALDH1A1 (0.41) | CYP19A1TRPV1NPC1RAB9AALDH1A1 | |
| SCHEMBL22134735 | 0.80 | TRPV1 (0.46) | TRPV1NPC1RAB9AMAPT | |
| SCHEMBL9883695 | 0.80 | TRPV1 (0.46) | TRPV1NPC1RAB9AMAPT | |
| SCHEMBL25815131 | 0.79 | CYP19A1 (0.41) | CYP19A1TRPV1RAB9AALDH1A1MAPT | |
| SCHEMBL22134641 | 0.78 | TRPV1 (0.43) | CYP19A1TRPV1NPC1RAB9AALDH1A1 | |
| SCHEMBL22134634 | 0.78 | CYP19A1 (0.39) | CYP19A1TRPV1NPC1RAB9AMAPT | |
| SCHEMBL22134742 | 0.77 | TRPV1 (0.39) | CYP19A1TRPV1NPC1RAB9AALDH1A1 | |
| SCHEMBL12744647 | 0.77 | TRPV1 (0.46) | TRPV1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219919-A1 | LITHIUM EXTRACTION WITH CROWN ETHERS | ORCA HOLDINGS, LLC | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219919-A1 | LITHIUM EXTRACTION WITH CROWN ETHERS | LCLAT1, LCT, IGF2R | CYP19A1 4811/4885TRPV1 434/4885NPC1 583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.